Travere Therapeutics: FILSPARI Ongoing Growth Prospects Make Travere Compelling Buy
Travere Therapeutics' FILSPARI has two FDA approvals and is driving revenue growth, while TVTX shares have nearly tripled since August 2025.
NASDAQ
Cap as of Nov 13 1 story
Get TVTX news in Claude, ChatGPT or your own code. See plans
Travere Therapeutics' FILSPARI has two FDA approvals and is driving revenue growth, while TVTX shares have nearly tripled since August 2025.